Kiniksa Pharmaceuticals International (KNSA) Cash from Financing Activities (2018 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has 9 years of Cash from Financing Activities data on file, last reported at $12.1 million in Q2 2026.

• Quarterly Cash from Financing Activities rose 13.2% year-over-year to $12.1 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $37.7 million (up 69.26% YoY) and the FY2025 annual result came in at $33.0 million, up 169.22% from the prior year.
• Cash from Financing Activities grew to $12.1 million in Q2 2026, from $6.1 million in the prior quarter.
• In the past five years, Cash from Financing Activities ranged from a high of $12.1 million in Q2 2026 to a low of -$178000.0 in Q2 2024.
• A 5-year average of $3.7 million and a median of $1.7 million in 2022 frame the typical range for Cash from Financing Activities.
• Annual changes were most pronounced in 2024 — Cash from Financing Activities plunged 212.66% — and 2025, when it jumped 6110.11%.
• Tracing KNSA's Cash from Financing Activities over 5 years: stood at $1.2 million in 2022, then sank by 41.6% to $695000.0 in 2023, then soared by 208.2% to $2.1 million in 2024, then soared by 257.52% to $7.7 million in 2025, then soared by 58.14% to $12.1 million in 2026.
• The last three Cash from Financing Activities figures came in at $12.1 million (Q2 2026), $6.1 million (Q1 2026), and $7.7 million (Q4 2025), per Business Quant data.